Concepedia

Todd Hager

TH

Statistics

Publications

14

Citations

2.1K

H-Index

13

Active since

2009

Affiliations

Amgen (United States)(Current)

Todd Hager is an author at Amgen (United States) specializing in endocrinology, metabolic regulation, and pharmacology.

Publications per year

2009–2024

14

Publications

14

Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models—association with liver and adipose tissue effects

Jing Xu, Shanaka Stanislaus, Narumol Chinookoswong et al. · American Journal of Physiology-Endocrinology and Metabolism · 2009 · 338 citations

, , +17

Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models

Elizabeth A. Killion, Jinghong Wang, Junming Yie et al. · Science Translational Medicine · 2018 · 224 citations · Full text

, , +17

Treating Diabetes and Obesity with an FGF21-Mimetic Antibody Activating the βKlotho/FGFR1c Receptor Complex

Ian N. Foltz, Sylvia Hu, Chadwick King et al. · Science Translational Medicine · 2012 · 211 citations

, , +14

A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings

Murielle M. Véniant, Shu-Chen Lu, Larissa Atangan et al. · Nature Metabolism · 2024 · 188 citations · Full text

, , +17

FGF19-induced Hepatocyte Proliferation Is Mediated through FGFR4 Activation

Xinle Wu, Hongfei Ge, Bryan D. Lemon et al. · Journal of Biological Chemistry · 2009 · 180 citations · Full text

, , +17

1–5 of 14